The aim of treatment in congenital adrenal hyperplasia is to suppress excess adrenal androgens while achieving physiological glucocorticoid replacement. However, current glucocorticoid replacement regimes are inadequate because doses sufficient to suppress excess androgens almost invariably induce adverse metabolic effects. Although both cortisol and corticosterone are glucocorticoids that circulate in human plasma, any physiological role for corticosterone has been neglected. In the brain, the adenosine 5′-triphosphate-binding cassette transporter ABCB1 exports cortisol but not corticosterone. Conversely, ABCC1 exports corticosterone but not cortisol. We show that ABCC1, but not ABCB1, is expressed in human adipose and that ABCC1 inhibition increases intracellular corticosterone, but not cortisol, and induces glucocorticoid-responsive gene transcription in human adipocytes. Both C57Bl/6 mice treated with the ABCC1 inhibitor probenecid and FVB mice with deletion of Abcc1 accumulated more corticosterone than cortisol in adipose after adrenalectomy and corticosteroid infusion. This accumulation was sufficient to increase glucocorticoid-responsive adipose transcript expression. In human adipose tissue, tissue corticosterone concentrations were consistently low, and ABCC1 mRNA was up-regulated in obesity. To test the hypothesis that corticosterone effectively suppresses adrenocorticotropic hormone (ACTH) without the metabolic adverse effects of cortisol, we infused cortisol or corticosterone in patients with Addison's disease. ACTH suppression was similar, but subcutaneous adipose transcripts of glucocorticoid-responsive genes were higher after infusion with cortisol rather than with corticosterone. These data indicate that corticosterone may be a metabolically favorable alternative to cortisol for glucocorticoid replacement therapy when ACTH suppression is desirable, as in congenital adrenal hyperplasia, and justify development of a pharmaceutical preparation.
INTRODUCTION
Congenital adrenal hyperplasia (CAH) is characterized by impaired adrenal steroidogenesis, with glucocorticoid deficiency resulting in reduced suppression of adrenocorticotropic hormone (ACTH) and, hence, ACTH-dependent adrenal androgen excess. Current treatment guidelines recommend cortisol (hydrocortisone) as the treatment of choice, but recent studies have found that the doses required to suppress adrenal androgen production are usually associated with adverse effects (1, 2) , notably in adipose tissue where chronic glucocorticoid excess promotes obesity and associated metabolic dysfunction (3) . The ideal treatment would have higher potency in suppressing ACTH and lower potency as a glucocorticoid acting in peripheral tissues. Here, we provide a rationale and proof of concept for using corticosterone therapy as an alternative to hydrocortisone (cortisol).
A neglected characteristic of the hypothalamus-pituitary-adrenal axis is that many species produce two glucocorticoids, cortisol and corticosterone, unlike rats and mice that lack 17-hydroxylase (CYP17) in their adrenals and therefore secrete only corticosterone. Although results of human glucocorticoid receptor (GR) binding studies are inconsistent (4, 5) , both glucocorticoids appear to have similar affinities for mineralocorticoid receptors (6) and are subject to similar metabolism (7) . However, there is emerging evidence for tissue-specific responses to cortisol and corticosterone, mediated by differential susceptibility to transmembrane transport by ATP (adenosine 5′-triphosphate)-binding cassette (ABC) transporters (8) (9) (10) (11) (12) . In rodents, ABCB1 (also known as multidrug resistance protein 1 or p-glycoprotein) exports cortisol but not corticosterone across the blood-brain barrier (10, 12) . Disproportionately high corticosterone concentrations in cerebrospinal fluid and brain tissue suggest that the same mechanism operates in humans (10, 13) . Another transporter, ABCC1 (or multidrug resistance-related protein 1), exports corticosterone but not cortisol in vitro (11) . We show the expression of ABCC1, but not ABCB1, in human adipose tissue, report the in vitro and in vivo data that support the hypothesis that adipose tissue excludes corticosterone and is preferentially sensitive to cortisol, and provide proof of concept that corticosterone may be a useful therapy, especially when suppression of ACTH is desirable, as in CAH.
RESULTS

ABCC1, but not ABCB1, is expressed in human adipose
In a transcriptomic analysis of ABC transporters in healthy men, ABCC1, but not ABCB1, was highly expressed in subcutaneous adipose tissue (Fig. 1A and fig. S1 ). This pattern was confirmed by conventional reverse transcription polymerase chain reaction (RT-PCR) amplification in human adipose tissue and in differentiated human SimpsonGolabi-Behmel syndrome (SGBS) adipocytes (Fig. 1B) (14) , in which we also confirmed that ABCC1 protein and mRNA are regulated in parallel, for example, when we induced ABCC1 by incubation with lipopolysaccharide ( fig. S2 ). However, in murine adipose tissue, both ABCB1 and ABCC1 were expressed (Fig. 1C) . Publicly available data sets do not provide sufficient data to test for patterns of ABCB1 and ABCC1 expression in multiple species, but we also found selective adipose expression of ABCC1 but not ABCB1 in horse, another species in which both cortisol and corticosterone are in the circulation (Fig. 1D ).
ABCC1 preferentially exports corticosterone and confers sensitivity to cortisol in human adipocytes in vitro After incubation of SGBS adipocytes with cortisol or corticosterone for 24 hours, removal of extracellular steroid resulted in lower intracellular concentrations of corticosterone compared to those of cortisol over the subsequent 24 hours ( Fig. 2A) , suggesting active preferential export of corticosterone. This was confirmed and attributed to ABCC1 using the inhibitors MK571 (15) and probenecid (11) . MK571 concentrations (10 mM) sufficient to inhibit ABCC1-dependent export of calcein by~40% in SGBS cells ( fig. S3A ) (16) increased the accumulation of intracellular deuterated corticosterone, which was assessed qualitatively using coherent anti-Stokes Raman scattering (CARS) microscopy ( Fig.  2B) . Similarly, both MK571 and probenecid increased intracellular tritiated corticosterone much more so than tritiated cortisol (Fig. 2C) . Effects of MK571 and probenecid on corticosterone retention were time-dependent ( fig. S3B ) and dosedependent ( fig. S3, C and D) .
To test the consequences of ABCC1-mediated steroid transport for GR activation, we used A549 human epithelial cells (which express ABCC1 and GR) transfected with a glucocorticoid-responsive MMTV-luciferase reporter (17) . The response was greater to cortisol than to corticosterone without inhibition of ABCC1, and MK571 potentiated luciferase induction by corticosterone but not cortisol ( fig.  S4A ). In differentiated SGBS adipocytes, we tested a panel of known GR-responsive gene transcripts to determine a suitable candidate for assessing acute cortisol versus corticosterone sensitivity (Fig. 2D ). Of these, only PER1 was induced acutely (2 hours) by glucocorticoids, consistent with its rapid response (18) and high sensitivity (19) in other systems. Greater sensitivity to cortisol was shown compared to corticosterone for induction of PER1 transcription (Fig. 2D ). MK571 directly increased the amount of this transcript ( fig. S4B ), so probenecid was used alone as an ABCC1 inhibitor, reversing the differential sensitivity to cortisol over corticosterone (Fig. 2D) . Similar results were obtained after 24-hour incubations ( fig. S4C ). Finally, to confirm whether adipocytes are functionally more sensitive to cortisol than to corticosterone, SGBS preadipocytes were differentiated in the presence of glucocorticoid; cortisol, but not corticosterone, induced marked triglyceride accumulation over 21 days (Fig. 2E) . ) on an FVB genetic background were adrenalectomized and infused with corticosterone and cortisol by subcutaneous osmotic mini-pump for 7 days, followed by measurement of steroids in plasma and tissue by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Plasma analysis (Fig. 3A) indicated impaired clearance of glucocorticoids in Abcc1 −/− mice, with elevated steady-state concentrations of corticosterone and a trend of elevated cortisol, compared with control mice, but there was no difference in the circulating corticosterone/cortisol ratio. In the brain (Fig. 3B) , corticosterone concentrations were higher in Abcc1 −/− mice than in controls, consistent with increased plasma ABCA8  ABCC1  ABCA5  ABCE1  ABCC5  ABCA9  ABCD3  ABCE1  ABCA9  ABCG1  ABCC6  ABCB10  ABCB2  ABCC10  ABCB7  ABCA5  ABCF1  ABCA1  ABCC6  ABCD2  ABCF3  ABCD4  ABCA3  ABCB6  ABCC9  ABCC4  ABCA7  ABCF2  ABCF2  ABCC9  ABCA9  ABCG2  ABCB8  ABCC2  ABCB1  ABCB1  ABCG1  ABCB6  ABCF2  ABCB3  ABCB4  ABCA1 concentrations, and cortisol was low in both groups, consistent with exclusion of cortisol by ABCB1 (10). However, there was no effect of ABCC1 deficiency on the brain corticosterone/cortisol ratio. In contrast, in subcutaneous adipose tissue (Fig. 3C ), Abcc1 deficiency resulted in an elevated corticosterone/cortisol ratio, with a marked increase in corticosterone, but not cortisol, concentrations. To assess whether pharmacological inhibition of ABCC1 mimicked the effects of genetic deletion on adipose glucocorticoid concentrations, we treated mice with probenecid. Male C57Bl/6 mice underwent the same adrenalectomy and steroid infusion protocol as Abcc1 +/+ and Abcc1 −/− mice and were treated with probenecid (150 mg/kg per day) or vehicle (saline). Probenecid did not alter corticosterone or cortisol concentrations in the plasma (Fig. 3D ) or in the brain (Fig. 3E) ; however, consistent with the results from Abcc1 −/− mice, probenecid increased corticosterone, but not cortisol, concentrations in subcutaneous adipose tissue (Fig. 3F) .
To test the metabolic consequences of the increase in intra-adipose corticosterone concentrations with ABCC1 inhibition, we repeated the experiment with probenecid, adding an additional control group with no glucocorticoid infusion, and assessed the adipose tissue for glucocorticoid-responsive gene transcripts (Fig. 4) . Plasma corticosterone and cortisol concentrations were unaffected by probenecid in corticosteroid-infused groups, as before (Fig. 4A) , and below the lower limit of detection (0.5 ng/ml) in vehicle-treated adrenalectomized animals. Corticosteroid infusion reduced weight gain during the 7-day treatment (Fig. 4B ) and induced adipose expression of Per1, Atgl, Hsl, and Lpl (Fig. 4C) ; the effects on body weight and adipose Per1, Atgl, and Lpl were potentiated by probenecid (Fig. 4 , B and C).
Corticosterone concentrations are low in human adipose and not increased in obesity To compare endogenous cortisol and corticosterone concentrations in adipose tissue, and to test whether down-regulation of ABCC1 might enhance corticosterone action in adipose tissue in obese patients, we collected subcutaneous and visceral adipose biopsies during elective abdominal surgical procedures from six lean and six obese humans, with characteristics shown in table S1. ABCC1 mRNA transcripts were increased in obese subjects in both subcutaneous and visceral adipose (Fig. 5A ). Adipose tissue cortisol was readily measured in both adipose depots, as previously described (20) , and was not different between lean and obese subjects (Fig. 5B) . Corticosterone concentrations in lean and obese subjects were below or near the limit of detection by LC-MS/MS in both visceral and subcutaneous adipose tissue (Fig. 5B ).
Human adipose is less sensitive to corticosterone than cortisol Having established that selective expression of ABCC1 protects human adipose tissue from corticosterone, we then tested whether corticosterone is less potent than cortisol in inducing metabolic effects in adipose. This was achieved using doses of cortisol and corticosterone equipotent for ACTH suppression. We performed a randomized single-blind crossover study in patients with Addison's disease using sequentially increasing steady-state infusions of deuterated glucocorticoids, D 8 -corticosterone and D 4 -cortisol, which can be distinguished from residual endogenous glucocorticoids by mass spectrometry (21) . Characteristics of the study participants are summarized in table S2. Circulating concentrations of cortisol (sum of cortisol, D 4 -cortisol, and its active metabolite D 3 -cortisol) and corticosterone (D 8 -corticosterone alone; endogenous corticosterone was undetectable) indicated that serially increasing steady-state concentrations were achieved as intended (Fig. 6A) . Total steady-state concentrations tended to be higher for cortisol than for corticosterone, although the differences were not statistically significant, and there were no differences in free cortisol and corticosterone measured after equilibrium dialysis (in samples pooled between 260 and 330 min of infusion; free cortisol, 38.7 ± 8.2 nM and free corticosterone, 37.2 ± 4.7 nM). Neither ACTH concentrations at baseline nor their suppression during glucocorticoid infusion was different between cortisol and corticosterone (Fig. 6 , B and C, and Table 1 ). Among the biochemical −/− deletion or pharmacological inhibition in mice results in preferential accumulation of corticosterone in adipose tissue. (A to C) Adrenalectomized male wild-type (Abcc1 +/+ ) or ABCC1 knockout (Abcc1 −/− ) FVB mice were infused with corticosterone and cortisol for 7 days. (D and E) Adrenalectomized male C57Bl/6 mice were infused with corticosterone and cortisol, together with either probenecid or vehicle (saline), for 7 days. Plasma (A and D), brain (B and E), and subcutaneous adipose (C and F) corticosterone (C'one) and cortisol were quantified by LC-MS/MS and are presented as concentrations and as corticosterone/cortisol ratios (Ratio). All data are means ± SEM; n = 6 to 8 per group; *P < 0.05 versus Abcc1 +/+ (A to C), *P < 0.05 versus vehicle (D and E), Student's t test; exact P values are given in table S7.
markers of glucocorticoid action-glucose, insulin, glycerol, and free fatty acids-only free fatty acids rose during steroid infusion (Table 1) , perhaps because the infusions were short and the glucocorticoid concentrations achieved were within the physiological range (22) . Insulin concentrations fell, paradoxically, during steroid infusions. None of these plasma biochemical markers differed between D 8 -corticosterone and D 4 -cortisol infusion (Table 1) . However, in subcutaneous adipose biopsies obtained at the end of infusions, the acutely responsive glucocorticoid-responsive transcript PER1 was substantially higher and LPL was also modestly higher after D 4 -cortisol than D 8 -corticosterone infusion (Fig. 6D ).
DISCUSSION
Our findings shed light on tissue-specific responsiveness to cortisol and the often neglected "second" glucocorticoid corticosterone, mediated by local expression of steroid-selective ABC transporters. In combination (A) ABCC1 mRNA concentrations were upregulated in obese subcutaneous (SC) and visceral (Visc) adipose tissue (n = 6; *P < 0.05, **P < 0.01 versus lean, unpaired Student's t tests). (B) Adipose tissue cortisol concentrations were readily detectable, but corticosterone concentrations were low or below the limit of detection in subcutaneous and visceral adipose (samples below limit of detection are assigned a value of 0.86 pmol/g). Neither cortisol nor corticosterone differed between lean and obese participants. All data are means ± SEM; exact P values are given in table S7. a.u., arbitrary unit.
with tissue-specific expression of either mineralocorticoid or GRs and tissue-specific intracellular metabolism of corticosteroids, the availability of alternate endogenous glucocorticoids that are differentially transported out of target cells provides a mechanism for subtle control of the otherwise highly conserved pathway of glucocorticoid action. Moreover, as summarized in the schematic in Fig. 7 , our data show how this insight can be exploited to develop corticosterone as a potentially safer alternative to cortisol for glucocorticoid replacement therapy when ACTH suppression is desirable.
For in vitro studies, we used SGBS adipocytes, an established model of human adipocytes (14) , to show that in the absence of ABCB1, endogenous ABCC1 expression is sufficient to reduce intracellular corticosterone but not cortisol concentrations. An equilibrium in intracellular cortisol and corticosterone concentrations was reached after about 4 hours in adipocytes. Our CARS microscopy data suggest that glucocorticoids colocalize with lipid droplets within adipocytes, potentially resulting in their intracellular retention and explaining the slow turnover of cortisol in adipose tissue in vivo (20) . The magnitude of the effect of ABCC1 on steroid export appears to be substantial, with a three-to fourfold increase in intracellular corticosterone when ABCC1 is inhibited in SGBS cells and a twofold increase in adipose corticosterone in vivo in mice. In a physiological context, if the plasma glucocorticoid pool is composed of 90 to 95% cortisol and 5 to 10% corticosterone, as reported in previous studies (10, 13, 23-32) (table S3), the total (cortisol plus corticosterone) intra-adipose glucocorticoid pool may be reduced by as much as~7% as a result of ABCC1 activity. In a pathological context, we hypothesized that reduction of adipose ABCC1 in obesity might contribute to metabolic dysregulation through increased intra-adipose corticosterone. However, ABCC1 expression was increased in obese patients, suggesting a potential protective mechanism to limit adipose exposure to glucocorticoids, which is considered to be beneficial in obesity (3). Indeed, adipose glucocorticoid concentrations were consistent with ABCC1 acting as constitutive barrier to maintain very low corticosterone concentrations in human adipose tissue, even in obese individuals. In a pharmacological context, such as if corticosterone were used as glucocorticoid replacement therapy, the consequences of ABCC1 activity for the intra-adipose glucocorticoid pool could be much greater. We tested this in vivo in mice and humans.
Our findings in vivo support our cell-based work, with both genetic deletion and pharmacological inhibition of ABCC1, resulting in preferential accumulation of corticosterone over cortisol in the adipose tissue. Because 17a-hydroxylase, which is necessary to produce cortisol, is not expressed in mouse adrenals, we studied this in adrenalectomized mice infused with equal concentrations of both glucocorticoids. Plasma steroid concentrations achieved during infusion were similar within strains, but slightly higher in C57Bl/6 than in FVB mice, potentially reflecting strain-specific differences in glucocorticoid clearance. Abcc1 −/− mice, but not mice treated with probenecid, showed higher steady-state plasma concentrations of cortisol and corticosterone compared to wildtype controls, implicating ABCC1 in total glucocorticoid clearance; this effect, however, appears to require total loss of ABCC1 because it was not observed with a competitive inhibitor, probenecid. Notably, the only spontaneous phenotype reported in Abcc1 −/− mice is a reduced susceptibility to inflammation (33) , which may be mediated by systemic or intracellular corticosterone excess, but this has not been studied. Using probenecid, we showed that the increase in intra-adipose corticosterone concentrations with ABCC1 inhibition is sufficient to potentiate the induction of key lipolytic genes (Atgl and Hsl) and prevent weight gain.
To investigate the physiological and therapeutic implications of these findings, we performed a study of patients with Addison's disease, who lack endogenous glucocorticoids. We selected patients with Addison's disease rather than with CAH to avoid confounding effects of high androgen concentrations in the adipose tissue. Corticosterone is only available as an experimental tool for infusion and not as a licensed pharmaceutical; therefore, only short-term manipulation was possible. At similar concentrations of free cortisol and corticosterone, we found equipotent suppression of ACTH but substantially greater gene transcript induction in adipose tissue by cortisol. In adipose, cortisol induced greater transcript expression than did corticosterone not only for PER1, which is rapidly induced by glucocorticoids (18) and sensitive at low concentrations, which do not alter other glucocorticoid-responsive genes (19) , but also for LPL, a key enzyme involved in adipose triglyceride uptake. The lack of differences in circulating metabolic markers is likely attributable to the short duration of infusions and the glucocorticoid concentrations within the physiological range (22) ; previous studies have demonstrated that plasma glucose, insulin, and glycerol show responses only to several hours of "physiological" glucocorticoid infusion (34, 35) . It remains possible that there are intrinsic differences in transcriptional response to cortisol and corticosterone in human adipose tissue, even when the same concentrations of steroid are present, Table 1 . Plasma biochemistry during infusion of either deuterated cortisol or corticosterone in patients with Addison's disease. Data are means ± SEM of within-subject averages from samples obtained during each steady state infusion period. n = 9. Comparisons were performed by two-way repeated-measures ANOVA: only ACTH (P < 0.001), nonesterified fatty acids (NEFA) (P = 0.018), and insulin (P = 0.042) changed with duration of steroid infusion, but there were no differences between corticosterone or cortisol infusions and no significant interactions between steroid and duration. but this seems unlikely given our findings in SGBS adipocytes that cortisol is no more potent than corticosterone when ABCC1 is inhibited. Despite our confirmation that cortisol concentrations are disproportionately low in the mouse brain, and earlier observations of relatively low cortisol in human brain and cerebral spinal fluid (10, 13), we did not find that corticosterone was more effective than cortisol in suppressing ACTH. This may reflect the major feedback signal being mediated in the pituitary rather than higher centers within the brain, under nonstressed conditions. Nonetheless, the discrepancy between suppression of ACTH and induction of adipose PER1 and LPL by cortisol versus corticosterone supports our interpretation that adipose tissue is physiologically more responsive to cortisol than to corticosterone and that this can be exploited therapeutically. Synthetic glucocorticoids commonly used as glucocorticoid therapy, specifically prednisolone and dexamethasone, are not transported by ABCC1 (11) and so are likely to access adipose tissue similarly to cortisol. To validate and exploit these findings, it will therefore be important to develop a suitable pharmaceutical preparation of corticosterone. With longer-term therapy, corticosterone and cortisol effects can be compared in conditions requiring effective ACTH suppression such as CAH, Nelson's syndrome, and glucocorticoid-suppressible hyperaldosteronism. Although we have focused here on adipose tissue, differential expression of ABCB1 and ABCC1 may determine tissue-specific Fig. 7 . Differential effects of cortisol and corticosterone in brain versus adipose are conferred by tissue-specific expression of ABC transporters. In conventional glucocorticoid replacement therapy, cortisol (hydrocortisone) action in the brain is limited by export through ABCB1, but the absence of ABCB1 in human adipose tissue allows potent effects of cortisol on peripheral metabolism. With corticosterone therapy, the lack of transport by ABCB1 in the brain allows corticosterone to exert a potent effect to suppress ACTH, but in adipose tissue, corticosterone action is limited by ABCC1, protecting against adverse effects of corticosterone on peripheral metabolism.
responses to corticosterone and cortisol in other tissues as well. Adverse effects will need to be compared not only for metabolism and obesity but also for immune suppression and osteoporosis. Nevertheless, our findings suggest that the substantial investment required to develop a corticosterone-based drug product is worthwhile.
MATERIALS AND METHODS
Study design
To investigate the role of adipose ABCC1-regulating cortisol versus corticosterone action, we conducted studies in cells, mice, and humans, as detailed below. In vitro experiments were performed in triplicate with the number of experiments and outcomes defined in the figure legends. For in vivo studies in mice, experiments were approved by the institutional ethical committee and conducted under UK Home Office license in male mice aged 10 to 12 weeks at the start of the experiment. Sample sizes were chosen for 80% power to detect magnitudes of difference inferred from in vitro experiments at P < 0.05, with the number of mice and outcomes defined in figure legends. Mice of each genotype were randomly assigned to interventions within each experiment. The studies in humans were conducted with approval from the South East Scotland Research Ethics Committee and National Health Service Lothian Research and Development (13/SS/0210 for Addison's disease study and 10/S1102/39 for surgical adipose tissue collection study) and with written informed consent of participants. The surgical adipose tissue collection study was a case-control design comparing adipose tissue mRNA amounts in lean and obese participants randomly selected from those undergoing surgery. An initial exploratory study was conducted in n = 6 per group and showed results contradicting the hypothesis that ABCC1 transcripts are decreased in obesity, so the study was not expanded. For the Addison's disease study, eligible patients participated in a singleblind randomized crossover study comparing infusions of deuterated corticosterone and deuterated cortisol for effects on ACTH, adipose tissue mRNA, and circulating metabolic indices. Blinding of the clinical investigator was impractical because of the requirements for administration of different loading and infusion doses of cortisol and corticosterone, but samples were processed in the laboratory with blinded codes and only decoded for statistical analysis; patients were blinded to treatment. Sample size was calculated for 90% power to detect 20% difference in ACTH at P < 0.05. Inclusion/exclusion criteria for each study are detailed below. There were no dropouts, and no outliers were excluded from any studies.
Human adipose tissue microarray
Affymetrix microarray data were obtained from subcutaneous adipose biopsies of nine healthy men, aged 36.6 ± 2.1 years with body mass indices of 29.2 ± 2.1 kg/m 2 (36) . Probes for transcripts encoding ABC transporters were selected and ranked by transcript intensity (log 2 -transformed).
Polymerase chain reaction
Human tissue BioBank cDNA (Primerdesign Ltd.) was used as a template for the identification of ABC transporters in the human tissue of interest. Equine perirenal adipose tissue collection from clinical cases euthanized for reasons other than endocrine disease/systemic inflammation was approved by the University of Edinburgh Veterinary Ethics and Research Committee. Where applicable, total RNA extraction was carried out by centrifugation in QIAzol lysis reagent using an RNeasy mini kit (Qiagen), according to the manufacturer's instructions. RNA integrity was checked on a 1% agarose gel, after which complementary DNA (cDNA; 500 ng of RNA per reaction) was synthesized using a high-capacity cDNA kit (Invitrogen), according to the manufacturer's instructions. cDNA was used as a template for specific primers (Invitrogen; table S4) for RT-PCR and amplified using GoTaq DNA polymerase (Promega), as per the manufacturer's instructions, on a Techne thermocycler (95°C for 5 min; 35 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 30 s; 72°C for 5 min). Products were subjected to gel electrophoresis on a 2% agarose gel in tris-acetate-EDTA buffer (50× stock buffer: 2 M tris base, 1 M glacial acetic acid, 100 mM disodium EDTA) containing GelRed (Cambridge Bioscience). Gels were imaged using a gel documentation system (Uvitec). Product size was confirmed against a 100-base pair DNA ladder (Invitrogen).
In vitro studies SGBS cell culture. Human SGBS preadipocyte cells were a gift from M. Wabitsch from the University of Ulm, Germany (14) . Cells were maintained in high-glucose Dulbecco's modified Eagle's medium (DMEM)-F12 (Lonza), supplemented with fetal bovine serum (FBS) [10% (v/v)], penicillin (100 IU/ml), streptomycin (100 IU/ml), biotin (33 mM), and pantothenic acid (17 mM) at 37°C in 5% CO 2 . Differentiation was induced as previously described (37) . Cells were cultured in steroid-free medium for 24 hours before experimentation.
Primary cell culture. Subcutaneous adipose tissue samples were obtained from patients undergoing elective abdominal surgery at the Royal Infirmary of Edinburgh. Upon tissue collection, adipose was digested, and the stromal vascular fraction was isolated and differentiated as previously described (38) . In brief, after removal of connective tissue and blood vessels, adipose tissue was digested in collagenase type I (615 U/g of tissue; for 90 min at 37°C). After overnight plating in highglucose DMEM-F12 supplemented with FBS [10% (v/v)], penicillin (100 IU/ml), streptomycin (100 IU/ml), biotin (33 mM), and pantothenic acid (17 mM), cells were differentiated for 3 days using the above medium without serum, but with addition of triiodothyronine (1 nM), transferrin (10 mg/ml), insulin (66 nM), 3-isobutyl-1-methylxanthine (IBMX; 500 mM), dexamethasone (1 mM), and rosiglitazone (10 mM). From day 4 onward, cells were maintained in this differentiation medium but without IBMX, dexamethasone, or rosiglitazone.
Tritiated glucocorticoid retention assays. To measure uptake and retention of steroids, SGBS adipocytes were incubated in the presence of either corticosterone or cortisol (20 nM 1,2,6,7-3 H 4 -steroid and 480 nM unlabeled steroid) for 1, 4, 8, and 24 hours before being washed in phosphate-buffered saline (PBS), lysed in cellular lysis buffer (0.5% SDS), mixed with ProSafe FC+ liquid scintillation cocktail (Meridian Biotechnologies), and read for 1 min on a b-scintillation counter. A separate batch of SGBS adipocytes were incubated with steroids for 24 hours as described above, and then washed in PBS before fresh steroid-free medium was added to each well and the decline in intracellular 3 H-steroid content was measured at 1, 4, 8, and 24 hours.
To assess the effect of ABCC1 inhibition, SGBS adipocytes were preincubated for 1 hour in the presence of the indicated concentrations of MK571 (Cayman Chemical), probenecid (Invitrogen), or vehicle [dimethyl sulfoxide (DMSO)], before being incubated for a further 24 hours in the presence of inhibitor or vehicle and either corticosterone or cortisol (20 nM washed in PBS, lysed in cellular lysis buffer, mixed with liquid scintillation cocktail, and read for 5 min on a b-scintillation counter.
Quantification of glucocorticoid-sensitive mRNA transcripts. In accordance with the time course of the clinical study, we performed an acute (2-hour) treatment in SGBS adipocytes and an extended (24-hour) treatment with either vehicle or cortisol (500 nM) to identify acutely up-regulated glucocorticoid-responsive transcripts. To determine the effects of ABCC1 inhibition on glucocorticoid-induced transcripts, SGBS adipocytes were preincubated for 1 hour in the presence of probenecid (50 mM) or vehicle (DMSO), before a further 2 or 24 hours of incubation in the presence of probenecid or vehicle and either corticosterone or cortisol (500 nM). Total RNA was extracted from adipocytes in QIAzol lysis reagent using an RNeasy Mini Kit according to the manufacturer's instructions. RNA (250 ng) was reverse-transcribed with random primers using the Applied Biosystems High-Capacity cDNA Reverse Transcription kit. Real-time PCR was performed using the Roche LightCycler 480 (Roche Applied Science). Primers (Invitrogen) were designed for use with intron-spanning probes within the Roche Universal Probe Library (UPL). Primer sequences and UPL probe numbers are shown in table S5. Results were corrected for abundance of 18S, which was not affected by treatment. All samples were analyzed in triplicate, and amplification curves were plotted (y axis, fluorescence; x axis, cycle number). Triplicates were deemed acceptable if the SD of the crossing point was <0.5 cycles. A standard curve (y axis, crossing point; x axis, log concentration) for each gene was generated by serial dilution of cDNAs pooled from different samples, fitted with a straight line, and deemed acceptable if reaction efficiency was between 1.7 and 2.1.
CARS microscopy. CARS microscopy is a noninvasive, label-free imaging technique based on Raman spectroscopy. The experimental setup has been described previously (39) . Briefly, a pump and tuneable Stokes laser (picoTrain, High-Q laser, and Levante Emerald optical parametric oscillator) provided a specific vibrational coherence, resulting in detectable photons that, when combined with a confocal laser scanning inverted microscope (C1 Eclipse, Nikon BV), provided a spatial image. For CARS imaging, the pump and Stokes laser beams were tuned such that the frequency difference would correspond to a specific Raman vibration. SGBS adipocytes were incubated for 24 hours in glass bottom dishes with 2,2,4,6,6,17a,21,21- ), which was in a region of the Raman spectrum with low background signal. Images were processed using Nikon EZ-C1 3.4 software.
Protein analysis. Total protein extracts from cells were prepared in radioimmunoprecipitation assay buffer (Santa Cruz Biotechnology). Samples were sonicated and centrifuged (13,000g, 15 min at 4°C) before performing the bicinchoninic acid assay, adding 6× Laemmli sample buffer, boiling, and performing SDS-polyacrylamide gel electrophoresis resolution. ABCC1 (ALX-801-007, Enzo Life Sciences) and HSP90 (sc-7947, Santa Cruz Biotechnology) were detected on Western blots using commercial antibodies.
Oil Red O staining and lipid quantification. To assess potential differing effects of cortisol and corticosterone on adipocyte differentiation, SGBS adipocytes were stimulated to undergo differentiation with or without the substitution of cortisol in the differentiation cocktail (37) for corticosterone. Accumulation of lipid during adipogenesis was visualized using Oil Red O (Sigma-Aldrich). Cells were washed twice with PBS and fixed with formalin [10% (v/v)] for 60 min, followed by a wash with isopropanol [60% (v/v)]. Working Oil Red O solution was added to cells for 10 min, followed by four washes with H 2 O. Cells were air-dried and dye-extracted with isopropanol (100%). Absorbance of extracts was measured at a 500-nm wavelength in an OptiMax microplate reader (Molecular Devices).
Calcein-acetoxymethyl ester assay. Calcein-acetoxymethyl ester (AM) is a nonfluorescent, hydrophilic, cell membrane-permeable molecule, which is converted to fluorescent, hydrophilic calcein by intracellular esterases (16) . Both calcein-AM and calcein are substrates for ABCC1; thus, intracellular fluorescence is inversely proportional to ABCC1 activity. SGBS adipocytes were washed with PBS and preincubated for 1 hour in the presence of MK571 (10 mM) or vehicle (DMSO), before being incubated for a further 5 hours in the presence of inhibitor or vehicle and calcein-AM (1 mM; Invitrogen). Cells were washed three times in PBS, and then excitation absorbance was measured at 494 nm and emission absorbance was measured at 517 nm in an Infinite M1000 plate reader (Tecan). Data are expressed as percentage fluorescence of untreated control.
Luciferase reporter assay. Human epithelial A549 cells were grown in DMEM (Lonza), supplemented with FBS [10% (v/v)], penicillin (100 IU/ml), and streptomycin (100 IU/ml). Cells were seeded at 2 × 10 5 per 35-mm well. After overnight incubation, medium was replaced with Opti-MEM (Lonza), and cells were transfected using Lipofectamine 2000 (Invitrogen) with a total of 2 mg of DNA comprising 1 mg of pMMTV LTR-luciferase (17) and 1 mg of pKC275 (encoding b-galactosidase as internal control). After overnight incubation, medium was replaced with steroid-free medium, and cells were treated for 1 hour with MK571 (10 mM) before a 24-hour incubation with inhibitor and either corticosterone or cortisol (500 nM). Luciferase and b-galactosidase activities were measured in cell lysates as described previously (40) . b-Galactosidase activity was assayed using a Tropix GalactoLight Plus kit (Applied Biosystems). All transfections were carried out in triplicate, and the mean ratio of luciferase/b-galactosidase activities was calculated.
Animal studies
Animals. Male Abcc1 knockout mice (Abcc1
) and FVB controls (Abcc1 +/+ ) were purchased from Taconic. Male C57Bl/J mice were purchased from Charles River. Mice were bilaterally adrenalectomized under fluorothane anesthesia. After surgery, drinking water was replaced with 0.9% NaCl, and animals were allowed to recover for 7 days. An osmotic mini-pump (Alzet Model 2001; 1 ml/hour) delivering corticosterone (250 mg/day) and cortisol (250 mg/day) or vehicle [DMSO/ propylene glycol, 50:50 (v/v)] was inserted subcutaneously under anesthesia and left in place for 7 days. Abcc1 +/+ and Abcc1 −/− mice received no further treatment. C57Bl/6 mice were given daily subcutaneous injections of probenecid (150 mg/kg) or vehicle (saline). This dose was previously reported to inhibit transporter activity in vivo (41) . Seven days after osmotic pump implantation, animals were culled by decapitation. Plasma was extracted from trunk blood and stored at −20°C. Tissue was extracted and stored at −80°C.
Plasma and tissue steroid extraction and LC-MS/MS quantification.
Steroids were extracted from plasma by liquid-liquid extraction (chloroform, 10:1). Briefly, plasma (100 ml) was enriched with internal standard (D 4 -cortisol and epicorticosterone, 25 ng each). Chloroform (1 ml) was added and vortexed. Supernatant was reduced to dryness under oxygen-free nitrogen (OFN) at 60°C and reconstituted in mobile phase [70 ml of water per acetonitrile; 70:30 (v/v)]. Steroids were extracted from brain and adipose as previously described (20) Quantitative analysis of steroids was carried out by LC-MS/MS. Chromatographic separation was achieved using a Waters Acquity UPLC system, with detection on an AB Sciex QTRAP 5500 mass spectrometer operated with Analyst software version 1.6.1. The mass spectrometer was operated using the TurboIonSpray source, with nitrogen as the source, curtain and collision gas (40 and 60 psi; medium), source temperature of 550°C, spray voltage of 4.5 kV, and an entrance potential of 10 V. Compound-specific tuning was performed using methanolic solutions of steroids and isotopically labeled internal standards. The protonated molecular ions were subjected to collision-induced dissociation, and the most abundant precursor-product transitions were selected; mass/charge ratio (m/z), 347. 1% FA] by 6 min and a total run time, including reequilibration, of 9 min. The peak areas were integrated using Xcalibur software (Thermo Electron) and quantified against a calibration curve. Steroid concentrations presented are corrected for total tissue weight or plasma volume.
Quantification of glucocorticoid-sensitive mRNA transcripts. RNA analysis performed was as described above. Primer sequences and UPL probe numbers are shown in table S6. Results were corrected for abundance of the mean combination of 18S and Tbp, which was not affected by treatment.
Adipose tissue steroid concentrations and ABCC1 mRNA in lean and obese humans We recruited 12 subjects who were at the Royal Infirmary of Edinburgh for elective abdominal surgery for nonmalignant disease and who did not have systemic or local active inflammation. Paired adipose tissue samples were obtained intraoperatively from the subcutaneous and visceral depots, stored on dry ice then at −80°C, and extracted for steroid quantification as previously described (20) and for RNA analysis as described above.
Cortisol versus corticosterone infusion in patients with
Addison's disease Participants. Patients with Addison's disease were identified from the clinic database of the Edinburgh Centre for Endocrinology and invited to attend a screening visit, where written informed consent was obtained and eligibility was assessed through a medical questionnaire, physical examination, and routine blood tests. Inclusion criteria were a diagnosis of autoimmune Addison's disease and age >18 years. Exclusion criteria were alcohol intake >28 U/week; abnormal screening blood results (full blood count and renal, liver, and thyroid function tests); pituitary disease; pregnant or breastfeeding; anti-inflammatory glucocorticoid therapy by any route in the preceding 3 months; cardiac, renal, or liver failure; uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg); blood donation in the preceding 3 months (to avoid anemia); or research study participation in the preceding 6 weeks.
Study protocol. Participants attended for study visits on two occasions, separated by at least 1 week. Participants withheld hydrocortisone from 2:00 p.m. on the day before each study visit and omitted fludrocortisone (when prescribed) the morning before the study visit and on the morning of the study visit. They attended the clinical research facility at 8:00 a.m. after an overnight fast from 10:00 p.m. At t = −15 min, intravenous cannulae (18 gauge) were inserted in each antecubital fossa. At t = 0, saline infusion (0.9%, 125 ml/hour) was commenced through the cannula in the left arm, and blood samples were collected from the cannula in the right arm. At t = 60 min, infusion of deuterated glucocorticoid (D 8 -corticosterone or D 4 -cortisol) was commenced. Order of steroid infusion was allocated randomly, and study participants were blinded to the order of infusate. Blood samples were obtained at 10-to 20-min intervals in potassium EDTA tubes (2.7 ml) prechilled on wet ice and serum gel tubes (9 ml; both Monovette, Sarstedt). Potassium EDTA tubes were centrifuged at 4°C within 30 min of sampling; serum gel samples were left at room temperature for 30 to 45 min before centrifugation. Serum and plasma were stored at −80°C. At t = 330 min, a needle aspiration biopsy of subcutaneous abdominal adipose tissue was obtained as previously described (36) and stored at −80°C.
Laboratory analyses. In plasma, ACTH was quantified by enzyme-linked immunosorbent assay (ELISA) (IBL International) within 6 weeks of sampling, and NEFAs (Zen-Bio) and glycerol (Sigma-Aldrich) were quantified by colorimetric assays. In serum, glucocorticoids were quantified by LC-MS/MS, insulin by ELISA (DRG Diagnostics), and glucose by colorimetric assay (Cayman Chemical).
LC-MS/MS analysis was undertaken as described for animal samples above with the exception that 11a-epimers of corticosterone (epicorticosterone; m/z, 347.2 → 91.1, 121.1 at 69 V) and cortisol (epicortisol; m/z, 363.2 → 121.0, 77.0 at 29 and 101 V) were used as internal standards instead of D 8 -corticosterone and D 4 -cortisol.
To account for any differences in protein binding between cortisol and corticosterone, cortisol and corticosterone isotopologs were also measured by LC-MS/MS after equilibrium dialysis of plasma. To achieve the necessary sensitivity, samples were pooled for the final steady-state period from each infusion (260 to 330 min), and 4 × 1 ml of aliquots of plasma were dialyzed into 1.5 ml of PBS across 12-to 14-kD dialysis membrane (Medicell) for 16 hours at 37°C, as previously described (42) , before LC-MS/MS analysis of the pooled dialysate as above. Real-time quantitative PCR (qPCR) was carried out in adipose tissue as with SGBS cells above.
Statistical analysis
For cell-and mouse-based studies, comparisons were performed using two-way ANOVA with Bonferroni post hoc tests or unpaired Student's t tests as outlined in each figure legend. For the Addison's disease study, data from each steady state period (80 to 140, 160 to 240, and 260 to 330 min) were averaged, and comparisons between D 4 -cortisol and D 8 -corticosterone and the interaction with changes over time were performed using two-way ANOVA. Adipose tissue data were compared with paired Student's t tests. P values for statistically significant differences are presented in table S7. Table S1 . Characteristics of lean and obese study participants providing adipose biopsy samples during surgery. Table S2 . Characteristics of Addison's study participants. Table S3 . Summary of studies describing plasma corticosterone and cortisol concentrations in healthy subjects. Table S4 . Primer sequences for PCR and corresponding expected product size. Table S5 . Human primer sequences for qPCR and corresponding probe number from Roche UPL. Table S6 . Murine primer sequences for qPCR and corresponding probe number from Roche UPL. Table S7 . Summary table of exact P values (provided as an Excel file).
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